Pfizer considers raising bid for AstraZeneca
May 13 2014
The new offer will increase the value modestly above the current 50 pounds ($84.36) per share level while increasing the cash portion, two people familiar with the matter told Bloomberg.
Both Pfizer and AstraZeneca could not be reached for comment outside of business hours.
On May 2, AstraZeneca turned down a sweetened Pfizer cash and stock offer that valued the British company at 63 billion pounds ($106 billion).